Find all
associated with


Refine your query (more in Advanced-Search):
 Focus on the recent 5 years   Focus on the current year   Focus on the last 30 days   More choices ...
 Focus on articles with free fulltexts   More choices ...
 Do simple 'keyword' search (no query expansion)

[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 10 of about 1225376
1. Wiwanitkit V: Nitric oxide synthase and polycystic kidney disease. J Nephropharmacol; 2015;4(2):85-87

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nitric oxide synthase and polycystic kidney disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28197487.001).
  • [Journal-full-title] Journal of nephropharmacology
  • [ISO-abbreviation] J Nephropharmacol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Iran
  • [Keywords] NOTNLM ; Chronic kidney disease / Nitric oxide synthase / Polycystic kidney disease
  •  go-up   go-down


2. Ko SY, Chang YS, Park WS: Clinical response to inhaled nitric oxide in persistent pulmonary hypertension of the newborn. J Korean Med Sci; 1998 Oct;13(5):500-6
Hazardous Substances Data Bank. NITRIC OXIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical response to inhaled nitric oxide in persistent pulmonary hypertension of the newborn.
  • We observed clinical response to inhaled nitric oxide (iNO) in 12 neonates with persistent pulmonary hypertension of the newborn (PPHN).
  • Two infants showed no response to iNO (one diaphragmatic hernia and one suspected pulmonary hypoplasia).
  • We conclude that iNO therapy could improve oxygenation in high percentage of newborn infants with severe PPHN of various underlying conditions except pulmonary hypoplasia.
  • [MeSH-major] Nitric Oxide / therapeutic use. Persistent Fetal Circulation Syndrome / therapy. Vasodilator Agents / therapeutic use

  • Genetic Alliance. consumer health - Pulmonary Hypertension.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 9811179.001).
  • [ISSN] 1011-8934
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Vasodilator Agents; 31C4KY9ESH / Nitric Oxide
  • [Other-IDs] NLM/ PMC3054528
  •  go-up   go-down


3. Albert M, Corsilli D, Williamson DR, Brosseau M, Bellemare P, Delisle S, Nguyen AQ, Varin F: Comparison of inhaled milrinone, nitric oxide and prostacyclin in acute respiratory distress syndrome. World J Crit Care Med; 2017 Feb 04;6(1):74-78

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of inhaled milrinone, nitric oxide and prostacyclin in acute respiratory distress syndrome.
  • METHODS: Open-label prospective cross-over pilot study where fifteen adult patients with hypoxemic failure meeting standard ARDS criteria and monitored with a pulmonary artery catheter were recruited in an academic 24-bed medico-surgical intensive care unit.
  • Thereafter, inhaled milrinone (1 mg/mL) alone followed by inhaled milrinone in association with inhaled nitric oxide (iNO) was administered.
  • RESULTS: The majority of ARDS were of pulmonary cause (<i>n</i> = 13) and pneumonia (<i>n</i> = 7) was the leading underlying initial disease.
  • Other pulmonary causes of ARDS were: Post cardiopulmonary bypass (<i>n</i> = 2), smoke inhalation injury (<i>n</i> = 1), thoracic trauma and pulmonary contusions (<i>n</i> = 2) and aspiration (<i>n</i> = 1).
  • Two patients had an extra pulmonary cause of ARDS: A polytrauma patient and an intra-abdominal abscess Inhaled nitric oxide, epoprostenol, inhaled milrinone and the combination of inhaled milrinone and iNO had no impact on systemic hemodynamics.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Respir Crit Care Med. 1996 Mar;153(3):991-6 [8630585.001]
  • [Cites] J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Mar 1;877(7):657-60 [19201666.001]
  • [Cites] J Intensive Care Med. 2006 May-Jun;21(3):119-43 [16672636.001]
  • [Cites] Intensive Care Med. 2009 Jan;35(1):171-8 [18972099.001]
  • [Cites] N Engl J Med. 1993 Feb 11;328(6):399-405 [8357359.001]
  • [Cites] Am J Respir Crit Care Med. 1996 Dec;154(6 Pt 1):1671-7 [8970353.001]
  • [Cites] Can J Anaesth. 2005 Dec;52(10):1076-82 [16326679.001]
  • [Cites] Anesthesiology. 1995 Jun;82(6):1507-11 [7793662.001]
  • [Cites] Anesth Analg. 2011 Jun;112(6):1411-21 [21372277.001]
  • [Cites] N Engl J Med. 2005 Dec 22;353(25):2683-95 [16371634.001]
  • [Cites] Anesthesiology. 2002 Jun;96(6):1504-13 [12170067.001]
  • [Cites] Anesth Analg. 2001 Dec;93(6):1439-45, table of contents [11726420.001]
  • (PMID = 28224110.001).
  • [Journal-full-title] World journal of critical care medicine
  • [ISO-abbreviation] World J Crit Care Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Acute respiratory distress syndrome / Hypoxemia / Inhaled milrinone / Nitric oxide / Prostacyclin / Pulmonary hypertension
  •  go-up   go-down


Advertisement
4. Eslami SM, Moradi MM, Ghasemi M, Dehpour AR: Anticonvulsive Effects of Licofelone on Status Epilepticus Induced by Lithium-pilocarpine in Wistar Rats: a Role for Inducible Nitric Oxide Synthase. J Epilepsy Res; 2016 Dec;6(2):51-58

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anticonvulsive Effects of Licofelone on Status Epilepticus Induced by Lithium-pilocarpine in Wistar Rats: a Role for Inducible Nitric Oxide Synthase.
  • To evaluate probable role of nitric oxide (NO) system, L-arginine (60 mg/kg, i.p.
  • ), as a non-selective nitric oxide synthase (NOS) inhibitor; aminoguanidine (100 mg/kg, i.p.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28101475.001).
  • [ISSN] 2233-6249
  • [Journal-full-title] Journal of epilepsy research
  • [ISO-abbreviation] J Epilepsy Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Keywords] NOTNLM ; 5-lipoxygenase / Cyclooxygenase / Licofelone / Nitric oxide synthase / Status epilepticus
  •  go-up   go-down


5. Guillen-Del Castillo A, Sánchez-Vidaurre S, Simeón-Aznar CP, Cruz MJ, Fonollosa-Pla V, Muñoz X: Prognostic Role of Exhaled Breath Condensate pH and Fraction Exhaled Nitric Oxide in Systemic Sclerosis Related Interstitial Lung Disease. Arch Bronconeumol; 2017 Mar;53(3):120-127
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic Role of Exhaled Breath Condensate pH and Fraction Exhaled Nitric Oxide in Systemic Sclerosis Related Interstitial Lung Disease.
  • [Transliterated title] Valor pronóstico del pH en el condensado de aire exhalado y de la fracción exhalada de óxido nítrico en la enfermedad pulmonar intersticial asociada a esclerosis sistémica.
  • METHODS: Fraction exhaled nitric oxide (FeNO) and exhaled carbon monoxide (eCO) measured in EB, together with pH, nitrite, nitrate and interleukin-6 levels measured in EBC were prospectively analyzed in 35 patients with SSc.
  • EB and EBC biomarkers were determined at inclusion, and pulmonary function tests were annually performed during 4 years of follow-up.
  • In all patients studied, low EBC pH levels were associated with a decreased diffusing capacity for carbon monoxide (DLCO) during follow-up.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2016 SEPAR. Publicado por Elsevier España, S.L.U. All rights reserved.
  • (PMID = 28038794.001).
  • [ISSN] 1579-2129
  • [Journal-full-title] Archivos de bronconeumologia
  • [ISO-abbreviation] Arch. Bronconeumol.
  • [Language] eng; spa
  • [Publication-type] Journal Article
  • [Publication-country] Spain
  • [Keywords] NOTNLM ; Aire exhalado / Enfermedad pulmonar intersticial / Esclerosis sistémica / Exhaled breath / Interstitial lung disease / Nitric oxide / Systemic sclerosis / pH / Óxido nítrico
  •  go-up   go-down


6. Feng JX, Lin Y, Lin J, He SS, Chen MF, Wu XM, Xu YZ: Relationship between Fractional Exhaled Nitric Oxide Level and Efficacy of Inhaled Corticosteroid in Asthma-COPD Overlap Syndrome Patients with Different Disease Severity. J Korean Med Sci; 2017 Mar;32(3):439-447
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relationship between Fractional Exhaled Nitric Oxide Level and Efficacy of Inhaled Corticosteroid in Asthma-COPD Overlap Syndrome Patients with Different Disease Severity.
  • This study explored the relationship between the fractional exhaled nitric oxide (FeNO) level and the efficacy of inhaled corticosteroid (ICS) in asthma-chronic obstructive pulmonary disease (COPD) overlap syndrome (ACOS) patients with different disease severity.
  • We compared FeNO levels, pulmonary function parameters including percentage of forced expiratory volume in 1 second (FEV1) to predicted value (FEV1%pred), ratio of FEV1 to forced vital capacity (FEV1/FVC), inspiratory capacity to total lung capacity (IC/TLC) and residual volume to total lung capacity (RV/TLC), arterial blood gas parameters, including PH, arterial partial pressure of oxygen (PaO₂) and arterial partial pressure of carbon dioxide (PaCO₂), total serum immunoglobulin E (IgE), induced sputum eosinophil (EOS), plasma surfactant protein A (SP-A), plasma soluble receptor for advanced glycation end products (sRAGE), sputum myeloperoxidase (MPO), sputum neutrophil gelatinase-associated lipocalin (NGAL) and Asthma Control Test (ACT) scores, and COPD Assessment Test (CAT) scores.
  • [MeSH-major] Adrenal Cortex Hormones / therapeutic use. Asthma / drug therapy. Nitric Oxide / analysis. Pulmonary Disease, Chronic Obstructive / drug therapy
  • [MeSH-minor] Administration, Inhalation. Adult. Advanced Glycosylation End Product-Specific Receptor / blood. Aged. Biomarkers / blood. Biomarkers / metabolism. Blood Gas Analysis. Case-Control Studies. Female. Forced Expiratory Volume. Humans. Immunoglobulin E / blood. Lipocalin-2 / metabolism. Male. Middle Aged. Peroxidase / metabolism. Pulmonary Surfactant-Associated Protein A / blood. Respiratory Function Tests. Severity of Illness Index. Sputum / enzymology. Sputum / metabolism

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Chron Obstruct Pulmon Dis. 2015 Sep 24;10:2017-25 [26451099.001]
  • [Cites] J Allergy Clin Immunol. 2003 Nov;112(5):883-92 [14610474.001]
  • [Cites] Ann Allergy Asthma Immunol. 2014 Jan;112(1):18-22 [24331388.001]
  • [Cites] Respirology. 2016 Aug;21(6):1034-40 [27061430.001]
  • [Cites] Respiration. 2015;90(4):306-13 [26352833.001]
  • [Cites] Int J Chron Obstruct Pulmon Dis. 2015 Jul 30;10:1477-86 [26251587.001]
  • [Cites] Expert Opin Pharmacother. 2015;16(12):1845-60 [26194213.001]
  • [Cites] Eur Respir J. 2009 Sep;34(3):648-54 [19720809.001]
  • [Cites] J Chin Med Assoc. 2013 Jan;76(1):15-9 [23331776.001]
  • [Cites] Expert Rev Respir Med. 2016;10 (3):363-71 [26789845.001]
  • [Cites] J Allergy Clin Immunol. 2004 Jan;113(1):59-65 [14713908.001]
  • [Cites] Biomed Res Int. 2014;2014:420134 [24683548.001]
  • [Cites] Eur J Anaesthesiol. 2016 Apr;33(4):275-82 [26716866.001]
  • [Cites] Respir Med. 2014 Jun;108(6):830-41 [24636813.001]
  • [Cites] Ther Adv Chronic Dis. 2016 Jan;7(1):34-51 [26770668.001]
  • [Cites] Eur Respir J. 2011 Mar;37(3):516-22 [20595148.001]
  • [Cites] Clin Physiol Funct Imaging. 2011 Jan;31(1):26-31 [21143751.001]
  • [Cites] Eur Respir J. 2016 Sep;48(3):664-73 [27338195.001]
  • [Cites] Nitric Oxide. 2014 Aug 31;40:110-6 [25014062.001]
  • [Cites] Am J Respir Crit Care Med. 2011 Sep 1;184(5):602-15 [21885636.001]
  • [Cites] Cent Eur J Public Health. 2015 Dec;23(4):286-91 [26841140.001]
  • [Cites] Oncotarget. 2016 May 3;7(18):25010-21 [26843624.001]
  • [Cites] Chest. 2010 Aug;138(2 Suppl):11S-17S [20668013.001]
  • [Cites] Eur Respir J. 2014 Feb;43(2):421-9 [23794464.001]
  • [Cites] Allergol Int. 2016 Jul;65(3):266-71 [26822895.001]
  • [Cites] J Korean Med Sci. 2011 Oct;26(10):1265-9 [22022176.001]
  • [Cites] J Asthma. 2015;52(10):1054-9 [26287987.001]
  • [Cites] Respiration. 2014;87(5):364-71 [24732295.001]
  • [Cites] Int J Chron Obstruct Pulmon Dis. 2015 Oct 09;10:2169-76 [26491283.001]
  • [Cites] Am J Respir Cell Mol Biol. 2002 May;26(5):565-71 [11970908.001]
  • [Cites] Eur Respir J. 2016 Mar;47(3):751-68 [26846832.001]
  • [Cites] J Thorac Dis. 2014 Mar;6 Suppl 1:S146-51 [24672688.001]
  • [Cites] Am J Respir Crit Care Med. 2005 Apr 15;171(8):912-30 [15817806.001]
  • [Cites] Allergol Int. 2015 Oct;64(4):359-63 [26433532.001]
  • [Cites] Int J Chron Obstruct Pulmon Dis. 2016 Mar 04;11:479-87 [27019598.001]
  • [Cites] Health Technol Assess. 2015 Oct;19(82):1-330 [26484874.001]
  • [Cites] Tohoku J Exp Med. 2016;238(2):179-84 [26888697.001]
  • [Cites] J Allergy Clin Immunol Pract. 2016 Jul-Aug;4(4):691-696.e1 [27039239.001]
  • (PMID = 28145647.001).
  • [ISSN] 1598-6357
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 0 / Advanced Glycosylation End Product-Specific Receptor; 0 / Biomarkers; 0 / Lipocalin-2; 0 / Pulmonary Surfactant-Associated Protein A; 31C4KY9ESH / Nitric Oxide; 37341-29-0 / Immunoglobulin E; EC 1.11.1.7 / Peroxidase
  • [Keywords] NOTNLM ; Asthma-Chronic Obstructive Pulmonary Disease Overlap Syndrome / Efficacy / Fractional Exhaled Nitric Oxide / Inhaled Corticosteroid
  •  go-up   go-down


7. Al-Ali MK, Howarth PH: Exhaled nitric oxide levels in exacerbations of asthma, chronic obstructive pulmonary disease and pneumonia. Saudi Med J; 2001 Mar;22(3):249-53
Hazardous Substances Data Bank. NITRIC OXIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Exhaled nitric oxide levels in exacerbations of asthma, chronic obstructive pulmonary disease and pneumonia.
  • OBJECTIVE: Nitric oxide is known to be present in the exhaled air of normal subjects and at higher concentrations in asthmatics.
  • The aim of this study was to measure exhaled nitric oxide levels in patients admitted to hospital with acute exacerbations of asthma, or chronic obstructive pulmonary disease, or with pneumonia.
  • METHODS: Within 24 hours of admission exhaled nitric oxide levels were measured by a chemiluminescent analyzer in 11 patients with acute sever asthma, 19 patients with acute exacerbation of chronic obstructive pulmonary disease, and in 12 patients with pneumonia.
  • RESULTS: On admission median exhaled nitric oxide levels (range) were significantly higher in asthmatics 22 (9.3-74) parts per billion in comparison to patients with chronic obstructive pulmonary disease 10.3 (2.7-34) parts per billion; p < 0.01, pneumonia 7 (4-17) parts per billion; p<0.001, and normal subjects 8.7 (5-13.3) parts per billion; p < 0.001.
  • Following treatment the asthmatics had a significant reduction in their exhaled nitric oxide levels from 22 (9.3-74) parts per billion on day 1 to 9.7 (5.7-18.3) parts per billion on day 28; p = 0.005.
  • A strong negative correlation existed between peak expiratory flow rate measurements and exhaled nitric oxide levels in asthmatics on day 28 (r = -0.70; p = 0.017).
  • CONCLUSION: Acute exacerbations of asthma are associated with increased levels of exhaled nitric oxide in contrast to exacerbations of chronic obstructive pulmonary disease and acute pneumonia.
  • Exhaled nitric oxide may be a useful indirect marker of asthmatic airway inflammation.
  • The differing time course of response of nitric oxide to peak flow measures suggests that these two measures are reflecting differing airway events.
  • [MeSH-major] Asthma / metabolism. Breath Tests. Lung Diseases, Obstructive / metabolism. Nitric Oxide / analysis. Pneumonia / metabolism


8. Barrington KJ, Finer N, Pennaforte T: Inhaled nitric oxide for respiratory failure in preterm infants. Cochrane Database Syst Rev; 2017 01 03;1:CD000509

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhaled nitric oxide for respiratory failure in preterm infants.
  • BACKGROUND: Inhaled nitric oxide (iNO) is effective in term infants with hypoxic respiratory failure.
  • OBJECTIVES: To determine effects of treatment with inhaled nitric oxide (iNO) on death, bronchopulmonary dysplasia (BPD), intraventricular haemorrhage (IVH) or other serious brain injury and on adverse long-term neurodevelopmental outcomes in preterm newborn infants with hypoxic respiratory failure.Owing to substantial variation in study eligibility criteria, which decreases the utility of an overall analysis, we divided participants post hoc into three groups:.
  • (1) infants treated over the first three days of life because of defects in oxygenation, (2) preterm infants with evidence of pulmonary disease treated routinely with iNO and (3) infants treated later (after three days of age) because of elevated risk of BPD.
  • SELECTION CRITERIA: Eligible for inclusion were randomised and quasi-randomised studies in preterm infants with respiratory disease that compared effects of iNO gas versus control, with or without placebo.
  • Four studies examining routine use of iNO in infants with pulmonary disease reported no significant reduction in death or BPD (typical RR 0.94, 95% CI 0.87 to 1.02; 1924 infants), although this small effect approached significance.
  • Early rescue treatment was associated with a non-significant 20% increase in severe IVH.We found no effect on the incidence of neurodevelopmental impairment.
  • [MeSH-major] Infant, Premature, Diseases / therapy. Nitric Oxide / administration & dosage. Respiratory Insufficiency / therapy. Vasodilator Agents / administration & dosage

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [UpdateOf] Cochrane Database Syst Rev. 2010 Dec 08;(12):CD000509 [21154346.001]
  • (PMID = 28045472.001).
  • [ISSN] 1469-493X
  • [Journal-full-title] The Cochrane database of systematic reviews
  • [ISO-abbreviation] Cochrane Database Syst Rev
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Research Support, N.I.H., Extramural; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Vasodilator Agents; 31C4KY9ESH / Nitric Oxide
  •  go-up   go-down


9. Tratsiakovich Y, Kiss A, Gonon AT, Yang J, Sjöquist PO, Pernow J: Inhibition of Rho kinase protects from ischaemia-reperfusion injury via regulation of arginase activity and nitric oxide synthase in type 1 diabetes. Diab Vasc Dis Res; 2017 May;14(3):236-245

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibition of Rho kinase protects from ischaemia-reperfusion injury via regulation of arginase activity and nitric oxide synthase in type 1 diabetes.
  • METHODS: Rats with streptozotocin-induced type 1 diabetes and non-diabetic rats were subjected to 30 min myocardial ischaemia and 2 h reperfusion after being randomized to treatment with (1) saline, (2) RhoA/Rho-associated kinase inhibitor hydroxyfasudil, (3) nitric oxide synthase inhibitor N<sup>G</sup>-monomethyl-l-arginine monoacetate followed by hydroxyfasudil, (4) arginase inhibitor N-omega-hydroxy-nor-l-arginine, (5) N<sup>G</sup>-monomethyl-l-arginine monoacetate followed by N-omega-hydroxy-nor-l-arginine or (6) N<sup>G</sup>-monomethyl-l-arginine monoacetate given intravenous before ischaemia.
  • RhoA/Rho-associated kinase inhibition and arginase inhibition significantly reduced infarct size in diabetic and non-diabetic rats ( p < 0.001).
  • The cardioprotective effects of hydroxyfasudil and N-omega-hydroxy-nor-l-arginine in diabetes were abolished by nitric oxide synthase inhibition.
  • RhoA/Rho-associated kinase inhibition attenuated myocardial arginase activity in diabetic rats via a nitric oxide synthase-dependent mechanism.
  • CONCLUSION: Inhibition of either RhoA/Rho-associated kinase or arginase protects from ischaemia-reperfusion injury in rats with type 1 diabetes via a nitric oxide synthase-dependent pathway.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28183205.001).
  • [ISSN] 1752-8984
  • [Journal-full-title] Diabetes & vascular disease research
  • [ISO-abbreviation] Diab Vasc Dis Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Diabetes / Rho kinase / arginase / ischaemia–reperfusion
  •  go-up   go-down


10. Endo A, Ayusawa M, Minato M, Takada M, Takahashi S, Harada K: Endogenous nitric oxide and endothelin-1 in persistent pulmonary hypertension of the newborn. Eur J Pediatr; 2001 Apr;160(4):217-22
Hazardous Substances Data Bank. NITRIC OXIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endogenous nitric oxide and endothelin-1 in persistent pulmonary hypertension of the newborn.
  • We studied changes in endogenous nitric oxide (NO) synthesis and endothelin-1 (ET-1) production in infants with persistent pulmonary hypertension of the newborn (PPHN).
  • CONCLUSION: Limited endogenous nitric oxide synthesis and elevated endogenous endothelin-1 production during the first few days of life may contribute to pulmonary hypertension in infants with persistent pulmonary hypertension of the newborn.
  • [MeSH-major] Endothelin-1 / blood. Nitric Oxide / blood. Persistent Fetal Circulation Syndrome / blood

  • Genetic Alliance. consumer health - Pulmonary Hypertension.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11317642.001).
  • [ISSN] 0340-6199
  • [Journal-full-title] European journal of pediatrics
  • [ISO-abbreviation] Eur. J. Pediatr.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Endothelin-1; 31C4KY9ESH / Nitric Oxide
  •  go-up   go-down






Advertisement